ClinicaliQ Trial Snapshot
- A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis — Recruiting • Phase I / Phase II • NCT04176198.
- Early-stage trial testing a new oral drug (nuvisertib) for safety and effectiveness in myelofibrosis patients.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This study is a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics and pharmacodynamics of nuvisertib (TP-3654) in patients with intermediate or high-risk primary or secondary MF. Conditions: Myelofibrosis Interventions: Nusivertib, Ruxolitinib, Momelotinib Lead Sponsor: Sumitomo Pharma America, Inc. Planned Enrollment: 240 participants